SEC Company Response from Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Mar 31, 2017
Altimmune, Inc. (ALT) (CIK 0001326190)
Date: March 31, 2017 · CIK: 0001326190 · Accession: 0001144204-17-018092
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-215891
Letter
United States VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance Attention: Suzanne Hayes, Assistant Director Re: PharmAthene, Inc. Amendment No. 2 to Registration Statement on Form S-4 Filed March 31, 2017 File No. 333-215891
Dear Ms. Hayes:
At the request of our client, PharmAthene, Inc. (the "Company"), we are responding to an oral comment of the staff (the "Staff") of the Division of Corporation Finance of the Securities and Exchange Commission (the "Commission") relating to Amendment No. 1 ("Amendment No. 1") to the Registration Statement on Form S-4 (the “Registration Statement”) filed with the Commission on March 30, 2017. In conjunction with this letter, the Company is filing Amendment No. 2 to the Registration Statement.
In response to the Staff's comment, the Company has provided the maximum number of shares to be issued on a fully-diluted basis on the cover page of the prospectus contained in Amendment No. 2.
*******
If you have any questions or require any additional information with respect to the above, please do not hesitate to contact me at (973) 912-7189.
Securities and Exchange Commission
March 31,
Page 2
大成 Salans FMC SNR Denton McKenna Long
dentons.com
Sincerely,
Dentons US LLP
Show Raw Text
CORRESP
1
filename1.htm
Jeffrey A. Baumel
Partner
jeffrey.baumel@dentons.com
D +1 973 912
7189
Dentons US LLP
101 JFK Parkway
Short Hills, NJ 07078-2708
United States
大成
Salans FMC SNR Denton McKenna Long
dentons.com
March 31, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Re: PharmAthene, Inc.
Amendment No. 2 to Registration Statement on Form S-4
Filed March 31, 2017
File No. 333-215891
Dear Ms. Hayes:
At the request of our client, PharmAthene,
Inc. (the "Company"), we are responding to an oral comment of the staff (the "Staff") of the Division of Corporation
Finance of the Securities and Exchange Commission (the "Commission") relating to Amendment No. 1 ("Amendment No.
1") to the Registration Statement on Form S-4 (the “Registration Statement”) filed with the Commission on March
30, 2017. In conjunction with this letter, the Company is filing Amendment No. 2 to the Registration Statement.
In response to the Staff's comment, the Company
has provided the maximum number of shares to be issued on a fully-diluted basis on the cover page of the prospectus contained in
Amendment No. 2.
*******
If you have any questions or require any
additional information with respect to the above, please do not hesitate to contact me at (973) 912-7189.
Securities and Exchange Commission
March 31,
2017
Page 2
大成
Salans FMC SNR Denton McKenna Long
dentons.com
Sincerely,
Dentons US LLP
By:
/s/ Jeffrey A. Baumel
Jeffrey A. Baumel
cc: John M. Gill, PharmAthene, Inc.
Ori Solomon, Proskauer Rose LLP